

Bio-Gene Technology Limited | ASX: BGT

Annual General Meeting

Developing new insecticides derived from nature to achieve high impact worldwide.

19 November 2025

Presentation

Tim Grogan

Managing Director & CEO



Important Notice & Disclaimer

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company's announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. No representation, warranty or guarantee, express or implied, is given that any Forward-Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward-Looking Statements are based are reasonable.

No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.

Bio-Gene Highlights

Developing two new insecticides with strong commercial validation.

01. Two New Actives

Two insecticidal compounds **derived from nature with novel modes of action:**

- » **Flavocide®** and **Qcide®** are derived from a unique sub-type of eucalypt
- » effectiveness against some major insect pests with resistance to standard products
- » Strong drivers are increasing the demand for **safer and more environmentally friendly** products

02. Large Target Markets

Crop Protection (incl. Grain Storage), **Public Health**, **Consumer**, **Animal Health**, total addressable markets of \$31B, as **both stand-alone and combination products**¹

03. Focused Pipeline

Pipeline of eight (formulated) product opportunities:

- » Public Health – vectors for disease
- » Crop Protection, Aquaculture, Professional Turf and Ornamentals
- » Grain Storage Protection
- » Consumer (home & garden)

04. Strong Partnering Progress

Three partnerships to date:

- » Clarke Mosquito (US), Evergreen Garden Care (EU, UK, AU & NZ), STK (Israel)

1. US EPA 2017, WHO 2017, Zoetis & Provue Market Research, Markets & Markets
 2. Qcide® and Flavocide® are registered trademarks of Bio-Gene Technology Limited.



Our Unique Products Derived from Nature

Qcide®

Qcide is an 100% natural oil extracted from the leaves of a specific cultivar of eucalypt (*Gypmie messmate*) currently farmed in northern Australia.

✓ *14th harvest in QLD completed in 2025*



Flavocide®

Flavocide is based on flavesone, a naturally occurring plant compound synthesised via a proprietary process that allows production in large volumes for global demand.






✓ *Pilot-scale production completed at Rallis India Ltd*



Patent families owned by Bio-Gene include: (1) Control of resistant pests.(2) Use in synergistic combinations, (3) Control of specific pests e.g., aphids, (4) Ovicidal activity against insect pests e.g., mites, bed bugs. Territories: Australia & New Zealand, USA/Europe, Latin America (Brazil), Asia (China), Africa (RSA)

Flavocide & Qcide – Multiple Market Segments








Bio-Gene is targeting five large well-developed global markets

Sectors					
	Crop Protection	Grain Storage	Public Health	Consumer Applications	Animal Health
	Food & Fibre	Stored Grain	Vector Control for Malaria, Zika & Dengue	Urban Pest Management, Oils, Lotions & Personal Repellents	Livestock & Pet-care Products
Size (US\$) & % of \$31.1B	\$16.1B 52%	\$1.0B 3%	\$4.0B 13%	\$4.1B 13%	\$5.9B 19%
Current Products & Challenges	<p>EU import restrictions (e.g. Omethoate for red-legged earth mite in Canola)</p> <p>Secondary regulation imposed by food chain (Aldi)</p> <p>Consumer and regulatory pressures</p>	<p>Pyrethroids, phosphine, organophosphates, etc.</p> <p>High levels of resistance in lesser grain borer, flat grain beetle, rice weevil</p>	<p>e.g. Bifenthrin, deltamethrin, pyrethrins, etc.</p> <p>Mosquito control market projected to grow by 38% between 2021-26¹</p>	<p>Mineral oils, toxic synthetics (e.g. malathion), pyrethum based products etc.</p> <p>Home and garden uses, Shift towards safe (especially to children & pets) and eco-friendly products to protect the environment</p>	<p>Japanese Encephalitis outbreaks</p> <p>Prevalence of ticks</p> <p>Consumer concerns for pet health</p>

1. Global Mosquito Control Professional Survey Report 2021, Forecast to 2026)

Flavocide & Qcide – Our Pipeline, Partners & Business Model


Bio-Gene is targeting five large well-developed global markets

Active constituent	Description	Sectors	Target uses	Partners & Collaborators
Flavocide	1 Grain Protectant	Crop protection	Admixture to grain	 GRDC GRAINS RESEARCH & DEVELOPMENT CORPORATION
	2 Outdoor Space Spray	Public health	Flying insects	 clarke
	3 Indoor Barrier Spray	Public health	Flying & crawling insects	 envu
	4 Outdoor Barrier Spray	Public health	Flying & crawling insects	 clarke
	5 Indoor Space Spray	Consumer	Flying insects	 EVERGREEN Garden Care
Qcide	6 Indoor Space Spray	Consumer	Flying insects	
	7 Outdoor Barrier Spray	Consumer	Flying insects	
	8 Outdoor Garden Spray	Crop protection & Consumer	Fruit & vegetables, ornamentals	 EVERGREEN Garden Care  stk bio-ag technologies

BGT is also investigating other potential use patterns, product extensions and combinations with other active ingredients.

Flavocide Development Path

Regulatory approval of a new active constituent and formulated product is a two-step process.



* Timeline updated on 1 May 2025 and will be updated in the near future based on studies currently in progress.

● Key inflection milestones that will generate increased revenue and interest from commercial partners

FY25 & Key Recent Achievements

Envu evaluating Flavocide® for mosquito management

Highlights

- Joint collaboration evaluating Flavocide® for mosquito management across a range of professional applications
- Flavocide complements the product pipeline of forward-thinking effective chemistries Envu offers for the global professional non-crop market
- Flavocide shown to effectively control mosquitoes



Flavocide® pilot-scale production by Rallis India Limited

Highlights

- Successful pilot-scale production of Flavocide® conducted by Rallis India Limited, one of India's leading Agri-sciences companies and a subsidiary of Tata Chemicals Limited
- Demonstration that Flavocide® can be produced at a consistent quality and yield at precommercial scale
- Flavocide® produced by Rallis India Limited to be used in planned testing activities to advance the registration process for Flavocide®
- Capacity to produce Flavocide® in sufficient quantities for future supply to Bio-Gene's commercial licensees



RALLIS INDIA LIMITED

APVMA feedback on Flavocide® development plan

Highlights

- Studies planned for the Flavocide® insect control active ingredient regulatory dossier are confirmed following feedback received from the Australian Pesticides and Veterinary Medicines Authority (APVMA)
- APVMA provides assistance on the regulatory requirements to facilitate registration of new active ingredients
- Flavocide is a novel insecticidal active ingredient derived from nature being developed by Bio-Gene for use in public health, agriculture and by consumers



Australian Government
Australian Pesticides and
Veterinary Medicines Authority

| FY25 & Key Recent Achievements

✓ Envu evaluation expanded to pest management

✓ Flavocide 5-batch analysis & GLP safety studies

✓ 14th Qcide harvest completed

✓ Formulation development expanded

✓ New patents granted and five new patent applications filed

✓ Partnering meetings in Singapore, India and Japan

✓ Successful Qcide seed and seedling production programs

✓ Completed review of pipeline and strategic partnering priorities

✓ Opportunities to develop and launch new products earlier

✓ Raised \$2.46m via Placement & Share Purchase Plan

| FY25 & Key Recent Achievements

Bio-Gene Awarded U.S. Department of Defense Grants Totalling A\$3.0m



Highlights

- **Two competitive grants totaling A\$3.0m (US\$1.9m) awarded to Bio-Gene under the U.S. Deployed Warfighter Protection (DWFP) program:**
 - **Grant 1 – A\$1.6M (US\$972,449) over three years to develop a wearable product containing Flavocide® to control mosquitoes and other insect vectors of disease**
 - **Grant 2 – A\$1.4M (US\$892,492) over three years to develop a sprayable formulation of Qcide® to provide residual control of flies and bed bug infestations**
- **The DWFP program is a U.S. Department of Defense program administered by the U.S. Armed Forces Pest Management Board that supports research and development of novel technologies to protect U.S. military personnel from threats posed by disease-carrying insect pests**
- **These grants are a strong validation of Bio-Gene’s technology and will enable development of two innovative products containing Flavocide® and Qcide® for commercialisation in both the military and civilian markets**

| FY25 & Key Recent Achievements

Positive Flavocide® Efficacy Results Presented at Leading Conference on Tick-borne Diseases



Highlights

- **Purdue University presents new Flavocide® efficacy results for tick control at the 17th International Conference on Lyme Borreliosis and Other Tick-Borne Diseases in the USA**
- **Laboratory efficacy studies confirm >90% mortality of *Ixodes scapularis* nymphs, a major vector of Lyme disease in the United States**
- **Residual activity in a prototype formulation of Flavocide was observed for up to four weeks post-application under laboratory conditions**
- **Findings confirm Flavocide's potential for use as a novel acaricide¹ against ticks and mites in public health and animal health applications**

| FY25 & Key Recent Achievements

Qcide® receives organic listing status in USA


Highlights

- The Organic Materials Review Institute (OMRI) based in the USA has evaluated Qcide® for compliance with the USDA National Organic Program (USDA NOP)
- Qcide® has been approved by OMRI for listing as a Botanical Pesticide under the USDA NOP in the OMRI Products List
- Strengthens Bio-Gene's commercial positioning of Qcide® for future use in a range of applications including in organic and sustainable pest control markets
- Qcide® is a natural, non-synthetic essential oil produced and being developed by Bio-Gene as a novel insecticide, derived from *Eucalyptus cloeziana* and extracted by steam distillation



Bio-Gene's Strategic Priorities

Strategy is focused on efficient development and approval of Flavocide and Qcide, with more commercial partnerships.



Key Forward Milestones & News Flow

Bio-Gene has many catalysts to drive value over the next 18 months, with a strong pipeline of near-term news flow.

01

Flavocide & Qcide development

- ✓ Flavocide regulatory studies (multiple)
- ✓ Submission of Flavocide regulatory dossier in Australia
- ✓ Flavocide scale-up milestones
- ✓ Qcide regulatory development milestones
- ✓ Qcide scale-up and harvest/processing progress
- ✓ Regulatory milestones

02

Partnering & commercial

- ✓ New commercial partnerships
 - Crop & grain storage
 - Vector control
 - Consumer uses
- ✓ Expansion of current licenses
- ✓ Receipt of milestone payments
- ✓ Patents granted

03

Funding & other support

- ✓ Grant funding successes
- ✓ Synergistic program/product opportunities
- ✓ International funding support & validation

Questions



Contact

Tim Grogan
Managing Director & CEO
timg@bio-gene.com.au

Matthew Wright
NWR Communications
matt@nwrcommunications.com.au
0451 896 420

ersonal use only